The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients’ sex

• Published in: International journal of cancer Vol. 145; no. 10; pp. 2840 - 2849
• Main Authors: Wang, Shixiang, Zhang, Jing, He, Zaoke, Wu, Kai, Liu, Xue‐Song
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 15.11.2019; Wiley Subscription Services, Inc
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological - pharmacology; Antineoplastic Agents, Immunological - therapeutic use; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - metabolism; Biomarkers; Cancer; Cancer immunotherapy; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - mortality; Datasets as Topic; DNA Mutational Analysis; Female; Gender differences; Humans; Immune checkpoint inhibitors; Immunotherapy; Kaplan-Meier Estimate; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - mortality; Male; Medical research; Middle Aged; Mutation Rate; PD-L1 protein; Predictive Value of Tests; Prognosis; Progression-Free Survival; ROC Curve; Sex differences; Sex Factors; Time Factors; tumor mutational burden; Whole Exome Sequencing; Young Adult; lung cancer; immune checkpoint inhibitors; tumor mutational burden; sex differences; cancer immunotherapy

Immunotherapy, represented by immune checkpoint inhibitors (ICI), is transforming the treatment of cancer. However, only a fraction of patients show response to ICI, and there is an unmet need for biomarkers that will identify patients more likely to respond to ICI. Here we report that the ICI respo...